uniQure N.V. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
uniQure announced updated Phase I/II data for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease as of June 30, 2026. At 36 months (n=15 high-dose): 80% slowing on cUHDRS (p=0.005) and 67% on TFC (p=0.011). At 48 months (n=12 high-dose): 44% slowing on cUHDRS (p=0.144, non-significant) and 61% on TFC (p=0.008). Clear dose-dependent response observed. BLA/MAA submissions based on 36-month data already made; 48-month analysis shows survivor bias in external control may understate true treatment effect.
Why this rating
Clinically meaningful data from lead asset supports regulatory pathway; modest patient numbers but consistent dose response strengthens case. Meaningful fraction of ~$765M market cap if approved transforms rare-disease trajectory.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.